page contents
 
Search
  • Anne

May 2022 Update!

Enhertu, which has shown statistically significant improvement in PFS when compared with Kadcyla (TDM1) as second-line treatment for HER2-positive MBC, has now been FDA-approved for HER2 positive adult patients who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. At a median follow-up of about 16 months in the DESTINY-Breast03 Phase 3 study, median Progression Free Survival was not reached with Enhertu and was 6.8 months with T-DM1. The benefit was observed across all prespecified subgroups, including patients with brain metastases. From: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer

66 views0 comments

Recent Posts

See All

An Experimental Drug Called Elacestrant May be FDA-Approved This Year! Possibly the most pivotal news divulged at the San Antonio Breast Cancer Symposium in Dec. 2021 was a study of an endocrine ther